2023 WCLC Highlights Webinar-2023 WCLC Highlights Webinar

Video Transcription

Video Summary

Summary: The webinar discussed two important abstracts from the 2023 World Conference on Lung Cancer. The first abstract focused on the new TNM staging edition. The ninth edition of the TNM staging system did not include any changes for T descriptors. However, the N2 category was split into N2A and N2B based on single station versus multiple station involvement. The M1C category was also modified to include M1C1 for single organ system involvement and M1C2 for multiple organ system involvement. The second abstract discussed the combination of immunotherapy and radiation therapy in early-stage non-small cell lung cancer. The iSABER trial found that adding immunotherapy to radiation therapy significantly improved four-year event-free survival compared to radiation therapy alone. However, confirmatory phase 3 trials are needed before this combination can be widely adopted. The webinar also briefly mentioned a retrospective study on the cardiovascular toxicity of immunotherapy. The study found that immunotherapy can cause cardiac events, including tachyarrhythmias, pericarditis, heart failure, and myocardial infarction. Baseline screening and close monitoring of cardiac function may be needed in patients receiving immunotherapy.

Asset Subtitle

This is the content subtitle section.

Meta Tag

Concept FLAURA2 Trial

Concept AEGEAN Trial

Concept AJCC/UICC TNM System

Concept Osimertinib

Concept EGFR Mutation

Keywords

webinar

abstracts

2023 World Conference on Lung Cancer

TNM staging edition

N2 category

M1C category

immunotherapy

radiation therapy

non-small cell lung cancer

FLAURA2 Trial

AEGEAN Trial

AJCC/UICC TNM System

Osimertinib

EGFR Mutation